TST test and cross-reactivity with the BCG vaccine
In Malaysia, the National BCG Vaccination Program, initiated in 1961, provided routine BCG vaccination to new-borns at birth. The vaccine is particularly useful in providing protection against disseminated tuberculosis such as tuberculous meningitis and military TB to children.
TST uses mixture proteins, sometimes referred to as purified protein TST uses mixture proteins, sometimes referred to as purified protein derivative (PPD), and these protein cross react with BCG and non-tuberculous Mycobacteria (NTM), leading to low specificity in patients with BCG vaccine. Low specificity means higher false positive results especially in children, which leads to overtreatment12.
Limitations with TST that are seen in BCG vaccinated populations absent when using IGRAs.
IGRAs are an in vitro diagnostic blood test, which detect interferon-gamma released by T cells after exposure to certain TB-specific antigens, as an indirect measure of adaptive cell immunity. The T-SPOT.TB test, which is a type of commercially-available IGRA test, uses TB-specific antigens ESAT-6 and CFP10. These antigens used are important because they are specific for MTB, and not present in the BCG vaccine or non-TB mycobacterium (NTM), limiting false reactions.